Mark Dysinger on the speed and sensitivity of Gyrolab biomarker assays

Mark Dysinger, Senior Scientist, Pharmacokinetics, Dynamics, and Metabolism, Pfizer Global Research and Development, presented ‘Glucagon-Like Peptide 1 Quantitation: Gyros vs Other Detection Platforms’ at the 2nd Annual North American Gyrolab Seminar, 2011, USA.

The Gyrolab assay speeded up turnaround considerably compared to assays based on ELISA and MSD technology:

  • 3 × faster assay development
  • 3 × shorter assay run time

In addition, the Gyrolab assay used minimal sample volumes and delivered over double the sensitivity of the other assays – critical factors in Mark’s application, measuring low levels of active GLP-1 in blood. In concluding, Mark regards Gyrolab xP workstation as an enabler, helping to get biopharmaceuticals onto the market sooner.

Note: To view the presentation on full screen, press ‘full screen’ before starting the presentation. Use ‘Outline’ to view selected sections of the presentation.